DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Freeman-Sheldon syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleFreeman-Sheldon syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for freeman-sheldon syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Freeman-Sheldon syndrome was diagnosed in an unrelated adult man and woman who had severe abnormalities of the extremities but only slight anomalies of the face. Electromyography and muscle biopsy showed a myopathy classified as congenital disproportion of fibre type, which appeared to be the primary cause of the deformities. This led the authors to classify the syndrome as a separate type of myopathic arthrogryposis.
The syndrome is a rare genetic disease inherited as an autosomal dominant trait in some families but showing sporadic appearance in the majority of reported cases. One paper reported a family with two affected children from normal consanguineous parents, suggesting that Freeman-Sheldon syndrome may be genetically heterogeneous.
A 2016 report described a female child with classical Freeman-Sheldon syndrome associated with a recurrent pathogenic heterozygous missense mutation, c.2015G > A, p. (Arg672His), in MYH3. The phenotypically normal mother was a molecularly confirmed mosaic for this mutation. This was the first report of molecularly confirmed parental mosaicism for a MYH3 mutation causing Freeman-Sheldon syndrome. Because proven somatic mosaicism after having an affected child is consistent with gonadal mosaicism, the authors advised a significantly increased recurrence risk and stated that parental testing is essential for accurate risk assessment for future pregnancies.
No drug treatment was studied or mentioned in any of these abstracts. What is missing is any clinical trial testing a pharmacological intervention, any funding for such a trial, and any molecular stratification of patients beyond the MYH3 mutation that might guide a repurposing strategy.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Medical Genetics · 1986 · 53 citations · open access
Freeman-Sheldon syndrome: a disorder of congenital myopathic origin?
AbstractFreeman-Sheldon syndrome was diagnosed in an unrelated adult man and woman, with severe abnormalities of the extremities but only slight anomalies of the face. Electromyography and muscle biopsy showed a myopathy which was classified as a congenital disproportion of fibre type and seemed to be the primary cause of the deformities. This allowed classification of the syndrome as a separate type of myopathic arthrogryposis.
Journal of Medical Genetics · 1977 · 40 citations · open access
Recessive form of Freeman-Sheldon's syndrome or 'whistling face',.
AbstractFreeman-Sheldon's syndrome is a rare genetic disease inherited as an autosomal dominant trait in some families but showing sporadic appearance in the majority of the reported cases. In the present paper we report a family having two affected children from normal consanguineous parents suggesting that Freeman-Sheldon's syndrome may be heterogeneous from the genetic point of view.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
